Exact Sciences Corporation (EXAS)
Valuation Overview•Is Exact Sciences Corporation Overvalued or Undervalued?
Priced at a premium to peer multiples and intrinsic cash flows, demanding strong execution to justify current levels.
Moderate quality score of 51/100, reflecting stable operating margins and manageable leverage.
Wall Street forecasts a balanced outlook with consensus price targets near the current price.
Verdict: Average quality business weighed down by significant profitability concerns.
Wall Street sentiment is generally neutral alongside robust expected earnings growth. However, capital return yields remain modest, driven predominantly by aggressive share repurchases.
EXAS struggles with subpar profitability and pressured margins. This is paired with a moderately leveraged but stable balance sheet.
The company is driving exceptional top-line expansion (15.9% 3Y CAGR) paired with stable bottom-line earnings. However, profitability remains a major concern with severely compressed operating margins (-6.4%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $878.4M | +17.7% | +15.9% | +16.8% | +55.4% | |
| EBITDA | -$82.6M | — | +19.5% | — | — | |
| Net Income | -$86.0M | +79.8% | +30.7% | — | -2.8% | |
| EPS (Diluted) | $-0.45 | +80.3% | — | — | +4.3% | |
| Free Cash Flow | $120.4M | +378.6% | — | +37.7% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 69.7% | 69.9% | 70.4% | 70.2% |
| Operating Margin | -6.4% | -17.7% | -26.0% | -45.8% |
| Net Margin | -6.4% | -17.3% | -23.1% | -44.5% |
| FCF Margin | 11.0% | 5.0% | -3.9% | -29.4% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q1'26Latest | $-0.11 | $-0.45 | -316.9% | ||
| Q4'25 | $-0.06 | $0.24 | +492.0% | ||
| Q3'25 | $-0.02 | $0.22 | +1200.0% | ||
| Q2'25 | $-0.37 | $-0.21 | +43.2% | ||
| Q1'25 | $-0.29 | $-0.06 | +79.3% | ||
| Q4'24 | $-0.20 | $-0.21 | -7.2% | ||
| Q3'24 | $-0.37 | $-0.09 | +75.7% | ||
| Q2'24 | $-0.47 | $-0.50 | -5.3% |
Total return is +100.4% (1Y), outperforming the benchmark by +75.4%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +3.1% | -6.2% | — |
| 1Y | +100.4% | +75.4% | — |
| 3YCAGR | +3.6% | -15.9% | — |
| 5YCAGR | -3.7% | -16.2% | — |
| 10YCAGR | +25.5% | +11.7% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Exact Sciences Corporation (EXAS) valuation, health, and returns.
Exact Sciences Corporation is estimated to be overvalued under our discounted cash flow framework. relative multiples indicate the stock is Expensive versus peers compared to industry peers. overvalued (implying -25.0% downside from DCF intrinsic value of $78.67)
Exact Sciences Corporation has multiple valuation anchors: DCF Intrinsic Value: $78.67 | Peer Relative Fair Value: $26.87 | Wall Street Analyst Target: $105.00 (implying +0.1% upside). A convergence of these signals offers higher conviction.
Exact Sciences Corporation displays fair financial health with a composite quality score of 51/100, supported by a Altman Z-Score of 2.4 (grey zone), Piotroski F-Score of 7/9, Return on Invested Capital (ROIC) of -3.6%.
Exact Sciences Corporation does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Exact Sciences Corporation's current growth trajectory is Stable. The company achieved +17.7% 1Y revenue growth and +80.3% 1Y EPS growth, compared to its 3Y revenue CAGR of +15.9%.
Wall Street consensus is Buy based on 41 analysts, beating EPS expectations in 75% of recent quarters with a -1-quarter streak. The consensus price target represents a +0.1% change from current levels.
Investment risks for Exact Sciences Corporation include: -26.0% 1-year max drawdown. Volatility risk is characterized by a beta of -0.07x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.